When was Minoryx founded?

Minoryx was founded in 2011 and raised its 1st funding round 2 years after it was founded.

Where is Minoryx located?

Minoryx is headquartered in Mataro, Spain. It is registered at Avenue Jean Mermoz 32 box 6 6041 Charleroi.

Who is the current CEO of Minoryx?

Marc Martinell of Minoryx. They have also founded 1 company.

How many employees does Minoryx have?

As of Jul 31, 2026, the latest employee count at Minoryx is 32.

Is Minoryx a funded company?

Minoryx is a funded company, having raised a total of $107M across 11 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 04, 2013.

When was the latest funding round of Minoryx?

Minoryx's latest funding was a $***** Series D round on Nov 10, 2022, with participation from 1 investor.

Where does Minoryx rank among its competitors?

Minoryx ranks 59th amongst 280 active competitors, of which 77 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Minoryx?

Minoryx's top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, BridgeBio secured the most recent funding round in April, 2024.

Minoryx - 2026 Company Profile, Team, Funding & Competitors

Minoryx is a series D company based in Mataro (Spain), founded in 2011 by Marc Martinell, Xavier Barril and Joan Aymami. It operates as a Developer of therapies for rare neurometabolic diseases. Minoryx has raised $107M in funding from investors like Caixa Capital Risc, Ysios Capital and Inveready. The company has 280 active competitors, including 77 funded and 98 that have exited. Its top competitors include companies like BridgeBio, Alnylam and PTC Therapeutics.

Company Details

Minoryx is a developer of therapies for rare neurometabolic diseases. It is also developing drugs for orphan diseases. The company targets inborn errors of metabolism that cause rare diseases of genetic origin. Its leading program, a PPAR gamma agonist (MIN-102) that has multiple CNS indications (phase 2/3) to treat X-ALD that is a genetic disease characterized by progressive neurologic deterioration. It is also working on non-competitive pharmacological chaperones identified through its proprietary platform Site-directed Enzyme Enhancement Therapy (SEE-Tx).

Website: www.minoryx.com/
Email ID: *****@minoryx.com
Phone Number: +34 **********
Registered Address: Avenue Jean Mermoz 32 box 6 6041 Charleroi

Key Metrics

Founded Year

2011

Location

Mataro, Spain

Stage

Series D

Total Funding

$107M in 11 rounds

Latest Funding Round

Series D, Nov 10, 2022, $*****

Investors

Caixa Capital Risc & 21 more

Ranked

59^th among 280 active competitors

Employee Count

32 as on Jul 31, 2026

Similar Companies

BridgeBio & 314 more

View Minoryx's full profile

Minoryx is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Minoryx Therapeutics BE CIN: 0713.984.534 , Belgium, Active	Nov 28, 2018	-	-	-

Minoryx has raised a total funding of $107M over 11 rounds. Its first funding round was on Apr 04, 2013. Its latest funding round was a Series D round on Nov 10, 2022 for $*****. 1 investor participated in its latest round. Minoryx has 22 institutional investors.

Here is the list of recent funding rounds of Minoryx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 10, 2022	5283055	Series D	2593250	2145777	3516223	5027720
May 31, 2022	1788285	Series C	6461085	2044100	3721082	CDTI & 2 more
May 31, 2022	7786032	Conventional Debt	6313221	8373018	5849801	Columbus Venture Partners & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Minoryx's funding rounds and investors

The founders of Minoryx are Marc Martinell, Xavier Barril and Joan Aymami. Marc Martinell is the CEO of Minoryx.

Here are the details of Minoryx's key team members:

Marc Martinell: Co-Founder & CEO of Minoryx.
Contact Info: 1 email address
Xavier Barril: Former Co-Founder of Minoryx.
Joan Aymami: Co-Founder of Minoryx.

View details of Minoryx's Founder profiles and Board Members

Minoryx's employee count trend

Minoryx has 32 employees as of Jul 26. Here is Minoryx's employee count trend over the years:

Uncover Minoryx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Minoryx include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Minoryx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
9th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	70/100
10th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
59th	Minoryx 2011, Mataro (Spain), Series D	Developer of therapies for rare neurometabolic diseases	$107M	Kurma Partners, Roche Enterprises & 20 others	57/100